Mylan

991 articles with Mylan

• 

  JPM Day 3: High Prices in San Francisco Are a Problem, Galapagos Strikes Fibrosis Deal

  1/16/2020

  While the conditions surrounding the City by the Bay are in a negative light, there is still a significant amount of positive news coming out of the conference.

• Mylan Initiates Voluntary Nationwide Recall of Three Lots of Nizatidine Capsules, USP, Due to the Detection of Trace Amounts of NDMA Impurity Found in the Active Pharmaceutical Ingredient Manufactured by Solara Active Pharma Scien

  1/8/2020

  Mylan N.V. announced that its U.S. based Mylan Pharmaceuticals business is conducting a voluntary nationwide recall, to the consumer level, of three lots of Nizatidine Capsules, USP.

• Mylan to Present at the 38th Annual J.P. Morgan Healthcare Conference

  1/6/2020

  Global pharmaceutical company Mylan N.V. announced that Chairman Robert J. Coury, together with Upjohn's Group President Michael Goettler and Mylan's President Rajiv Malik, will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, Calif., on Wednesday, Jan. 15, 2020 at 8:30 a.m. PT / 11:30 a.m. ET.

• 

  COPD Market Expected to Grow as Number of Cases Continues Rising

  11/27/2019

  While there is no cure for the disease, there are a number of drugs that have been approved to treat the illness. And with the growing number of cases, the drug market for COPD is expected to dramatically increase as well.
• 

  Mylan Manufacturing Site Flagged for Poor Controls Over Valsartan Production

  11/14/2019

  The letter outlines multiple failures, including failure to have adequate written procedures for the receipt, identification and handling of raw materials and failure to adequately clean equipment and utensils.

• Mylan and Pfizer Announce Viatris as the New Company Name in the Planned Mylan-Upjohn Combination

  11/12/2019

  Mylan N.V. and Pfizer Inc. announced that the name of the new company to be formed by the planned combination of Mylan and Upjohn, a division of Pfizer, will be Viatris.

• Mylan Reports Third Quarter 2019 Results and Updates 2019 Guidance

  11/5/2019

  Mylan N.V. announced its financial results for the three and nine months ended September 30, 2019.

• 

  Contaminant Causes Mylan to Issue Recall for Single Lot of Alprazolam, a Xanax Generic

  10/29/2019

  The batch being recalled has the lot number 8082708. Medication from this lot was sold between July and August of this year, the company said.

• Mylan to Release Third Quarter 2019 Financial Results on Nov. 5, 2019

  10/24/2019

  Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it will release its third quarter 2019 financial results on Tuesday, Nov. 5 before the open of the U.S. financial markets.

• Mylan Finalizes Previously Disclosed Settlement with U.S. Securities and Exchange Commission

  9/27/2019

  Mylan N.V. announced that it has finalized a previously disclosed civil settlement with the U.S. Securities and Exchange Commission.

• Eisai's Promotion and Distribution Agreement with Mylan India for Eribulin Second Brand in India

  9/25/2019

  Aiming to Expand Availability of Eribulin to Patients in India with Two Brands Halaven and Teceris

• Aiming to Expand Availability of Eribulin to Patients in India with Two Brands Halaven and Teceris

  9/20/2019

  Entered into a license agreement to promote and distribute the second brand TECERIS for the anticancer agent eribulin mesylate (eribulin) in India.

• Mylan Expands Oncology Portfolio with Launch of Generic Faslodex® Injection, a Treatment for Advanced Breast Cancer

  9/17/2019

  Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for this product, which is used to treat certain types of advanced breast cancer in women who have experienced menopause as monotherapy and in advanced or metastatic breast cancer in combination with other products.

• 

  Mylan's Newly-Approved Alimta Generic Will Not be Sold Until 2022

  8/30/2019

  The U.S. Food and Drug Administration (FDA) gave tentative approval to Mylan’s pemetrexed, a generic version of Eli Lilly’s $2 billion lung cancer drug, Alimta.
• 

  Novo Nordisk and Mylan Battle Over Generic Versions of Victoza

  8/22/2019

  Novo Nordisk filed a lawsuit in a Delaware district court against generic drugmaker Mylan. The suit is an attempt to block Mylan from marketing a generic version of Novo Nordisk’s diabetes drug Victoza.

• SHAREHOLDER ALERT: WeissLaw LLP Investigates Mylan N.V.

  7/30/2019

  WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Mylan N.V. in connection with the proposed acquisition of the Company by Pfizer Inc..

• Pfizer Inc. Reschedules Second-Quarter 2019 Earnings Conference Call to July 29, 2019 at 10:30 a.m. EDT

  7/29/2019

  Pfizer’s second-quarter 2019 earnings conference call with investment analysts has been rescheduled for, July 29, 2019, at 10:30 a.m. EDT.

• Statement from Mylan's Board of Directors Regarding Retirement of CEO and Board Member Heather Bresch in Conjunction with the Combination of Mylan and Upjohn, a Division of Pfizer

  7/29/2019

  Mylan's Board of Directors shared the following statement regarding Heather Bresch's retirement, which will be effective upon the closing of the combination of Mylan and Upjohn, a division of Pfizer.

• Mylan and Upjohn, a Division of Pfizer, to Combine, Creating a New Champion for Global Health Uniquely Positioned to Fulfill the World’s Need for Medicine

  7/29/2019

  Combines Mylan’s sustainable, diverse and differentiated portfolio of medicines with Upjohn’s trusted, iconic brands

• Mylan and Upjohn, a Division of Pfizer, to Combine, Creating a New Champion for Global Health Uniquely Positioned to Fulfill the World's Need for Medicine

  7/29/2019

  Mylan N.V. and Pfizer Inc. announced a definitive agreement to combine Mylan with Upjohn, Pfizer's off-patent branded and generic established medicines business, creating a new global pharmaceutical company.